Top

Open Access 03-05-2024 | Pharmacokinetics | Original Research Article

Retrospective Assessment of Translational Pharmacokinetic–Pharmacodynamic Modeling Performance: A Case Study with Apitolisib, a Dual PI3K/mTOR Inhibitor

Authors: Anita Moein, Jin Y. Jin, Matthew R. Wright, Bruno Alicke, Harvey Wong

Abstract

Background and Objectives

Despite significant progress in biomedical research, the rate of success in oncology drug development remains inferior to that of other therapeutic fields. Mechanistic models provide comprehensive understanding of the therapeutic effects of drugs, which is crucial for designing effective clinical trials. This study was performed to acquire a better understanding of PI3K–AKT–TOR pathway modulation and preclinical to clinical translational bridging for a specific compound, apitolisib (PI3K/mTOR inhibitor), by developing integrated mechanistic models.

Methods

Integrated pharmacokinetic (PK)–pharmacodynamic (PD)–efficacy models were developed for xenografts bearing human renal cell adenocarcinoma and for patients with solid tumors (phase 1 studies) to characterize relationships between exposure of apitolisib, modulation of the phosphorylated Akt (pAkt) biomarker triggered by inhibition of the PI3K–AKT–mTOR pathway, and tumor response.

Results

Both clinical and preclinical integrated models show a steep sigmoid curve linking pAkt inhibition to tumor growth inhibition and quantified that a minimum of 35–45% pAkt modulation is required for tumor shrinkage in patients, based on platelet-rich plasma surrogate matrix and in xenografts based on tumor tissue matrix. Based on this relationship between targeted pAkt modulation and tumor shrinkage rate, it appeared that a constant pAkt inhibition of 61% and 65%, respectively, would be necessary to achieve tumor stasis in xenografts and patients.

Conclusions

These results help when it comes to evaluating the translatability of the preclinical analysis to the clinical target, and provide information that will enhance the value of future preclinical translational dose-finding and dose-optimization studies to accelerate clinical drug development.

Trial Registry

ClinicalTrials.gov NCT00854152 and NCT00854126.

Available only for authorised users

Zhu AZ. Quantitative translational modeling to facilitate preclinical to clinical efficacy & toxicity translation in oncology. Future Sci OA. 2018;4(5):FSO306. https://doi.org/10.4155/fsoa-2017-0152.CrossRefPubMedPubMedCentral

Polivka J Jr, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther. 2014;142(2):164–75. https://doi.org/10.1016/j.pharmthera.2013.12.004.CrossRefPubMed

Vanhaesebroeck B, Perry MWD, Brown JR, Andre F, Okkenhaug K. PI3K inhibitors are finally coming of age. Nat Rev Drug Discov. 2021;20(10):741–69. https://doi.org/10.1038/s41573-021-00209-1.CrossRefPubMedPubMedCentral

Dolgin E. Cancer drug approvals and setbacks in 2022. Nat Cancer. 2022;3(12):1406–8. https://doi.org/10.1038/s43018-022-00482-y.CrossRefPubMed

2023 Guidance document. Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases. US Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/optimizing-dosage-human-prescription-drugs-and-biological-products-treatment-oncologic-diseases. Accessed 8 Jan 2023.

2023 Project Optimus. Reforming the dose optimization and dose selection paradigm in oncology. US Food and Drug Administration. https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus. Accessed 8 Jan 2023.

Bueno L, de Alwis DP, Pitou C, Yingling J, Lahn M, Glatt S, et al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer. 2008;44(1):142–50. https://doi.org/10.1016/j.ejca.2007.10.008.CrossRefPubMed

Wong H, Belvin M, Herter S, Hoeflich KP, Murray LJ, Wong L, et al. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy. J Pharmacol Exp Ther. 2009;329(1):360–7. https://doi.org/10.1124/jpet.108.148189.CrossRefPubMed

Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019;18(1):26. https://doi.org/10.1186/s12943-019-0954-x.CrossRefPubMedPubMedCentral

10.

Josephs DH, Sarker D. Pharmacodynamic biomarker development for PI3K pathway therapeutics. Transl Oncogenom. 2015;7(Suppl 1):33–49. https://doi.org/10.4137/TOG.S30529.CrossRef

11.

Owonikoko TK, Khuri FR. Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation. Am Soc Clin Oncol Educ. 2013. https://doi.org/10.14694/EdBook_AM.2013.33.e395.CrossRef

12.

Wallin JJ, Edgar KA, Guan J, Berry M, Prior WW, Lee L, et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther. 2011;10(12):2426–36. https://doi.org/10.1158/1535-7163.MCT-11-0446.CrossRefPubMed

13.

Dolly SO, Wagner AJ, Bendell JC, Kindler HL, Krug LM, Seiwert TY, et al. Phase I study of apitolisib (GDC-0980), dual phosphatidylinositol-3-kinase and mammalian target of rapamycin kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2016;22(12):2874–84. https://doi.org/10.1158/1078-0432.CCR-15-2225.CrossRefPubMedPubMedCentral

14.

Salphati L, Pang J, Plise EG, Lee LB, Olivero AG, Prior WW, et al. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human. Drug Metab Dispos. 2012;40(9):1785–96. https://doi.org/10.1124/dmd.112.046052.CrossRefPubMed

15.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16. https://doi.org/10.1093/jnci/92.3.205.

16.

Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15(2):257–60. https://doi.org/10.1093/annonc/mdh059.CrossRefPubMed

17.

Beal S, Boeckmann L, Bauer R, Sheiner L. NONMEM User’s Guides. (1989–2009). NONMEM User’s Guides (1989–2009). Elliot City: Icon Development Solutions; 2009.

18.

R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Vienna: R Core Team; 2019.

19.

Goldmacher GV, Conklin J. The use of tumour volumetrics to assess response to therapy in anticancer clinical trials. Br J Clin Pharmacol. 2012;73(6):846–54. https://doi.org/10.1111/j.1365-2125.2012.04179.x.CrossRefPubMedPubMedCentral

20.

Tanaka C, O’Reilly T, Kovarik JM, Shand N, Hazell K, Judson I, et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol. 2008;26(10):1596–602. https://doi.org/10.1200/JCO.2007.14.1127.CrossRefPubMed

21.

Yamazaki S, Skaptason J, Romero D, Lee JH, Zou HY, Christensen JG, et al. Pharmacokinetic–pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab Dispos. 2008;36(7):1267–74. https://doi.org/10.1124/dmd.107.019711.CrossRefPubMed

22.

Yates JW, Dudley P, Cheng J, D’Cruz C, Davies BR. Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363. Cancer Chemother Pharmacol. 2015;76(2):343–56. https://doi.org/10.1007/s00280-015-2795-7.CrossRefPubMed

23.

Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm. 1993;21(4):457–78. https://doi.org/10.1007/BF01061691.CrossRefPubMedPubMedCentral

24.

Mager DE, Wyska E, Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos. 2003;31(5):510–8. https://doi.org/10.1124/dmd.31.5.510.CrossRefPubMed

25.

Sutherlin DP, Bao L, Berry M, Castanedo G, Chuckowree I, Dotson J, et al. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J Med Chem. 2011;54(21):7579–87. https://doi.org/10.1021/jm2009327.CrossRefPubMed

26.

Sarker D, Ang JE, Baird R, Kristeleit R, Shah K, Moreno V, et al. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015;21(1):77–86. https://doi.org/10.1158/1078-0432.CCR-14-0947.CrossRefPubMed

27.

Tarantelli C, Lupia A, Stathis A, Bertoni F. Is there a role for dual PI3K/mTOR inhibitors for patients affected with lymphoma? Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21031060.CrossRefPubMedPubMedCentral

28.

Wong H, Alicke B, West KA, Pacheco P, La H, Januario T, et al. Pharmacokinetic–pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent hedgehog pathway activation. Clin Cancer Res. 2011;17(14):4682–92. https://doi.org/10.1158/1078-0432.CCR-11-0975.CrossRefPubMed

29.

Claret L, Gupta M, Han K, Joshi A, Sarapa N, He J, et al. Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer. J Clin Oncol. 2013;31(17):2110–4. https://doi.org/10.1200/JCO.2012.45.0973.CrossRefPubMed

30.

Wong H, Choo EF, Alicke B, Ding X, La H, et al. Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin Cancer Res. 2012;18(14):3846–55. https://doi.org/10.1158/1078-0432.CCR-12-0738.CrossRefPubMed

Title: Retrospective Assessment of Translational Pharmacokinetic–Pharmacodynamic Modeling Performance: A Case Study with Apitolisib, a Dual PI3K/mTOR Inhibitor
Authors: Anita Moein
Jin Y. Jin
Matthew R. Wright
Bruno Alicke
Harvey Wong
Publication date: 03-05-2024
Publisher: Springer International Publishing
Keywords: Pharmacokinetics
Biomarkers
mTOR-Inhibitors
Published in: Drugs in R&D
Print ISSN: 1174-5886
Electronic ISSN: 1179-6901
DOI: https://doi.org/10.1007/s40268-024-00459-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Retrospective Assessment of Translational Pharmacokinetic–Pharmacodynamic Modeling Performance: A Case Study with Apitolisib, a Dual PI3K/mTOR Inhibitor

Abstract

Background and Objectives

Methods

Results

Conclusions

Trial Registry

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background and Objectives

Methods

Results

Conclusions

Trial Registry

Please log in to get access to this content